Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A new class of drugs is changing the game for narcolepsy and hypersomnia. Sleep specialist Dr. KuangHua Guo highlights how orexin agonists — especially Takeda's newly FDA-approved oveporexton — dramatically outperform older stimulant-based treatments. With wakefulness improvements nearly five times greater than existing options, these drugs could soon become the go-to first-line therapy.
For decades, clinicians treating hypersomnia and narcolepsy relied on stimulants like modafinil or GABAergic agents like sodium oxybate — medications that kept patients awake but didn't address the underlying disease. That's now changing fast, thanks to a new wave of orexin agonist therapies targeting the actual pathophysiology of these conditions.
Dr. KuangHua Guo, a sleep specialist at Northwestern Medicine, sat down with NeurologyLive ahead of the 4th Annual Updates in Neurology CME Symposium to break down what clinicians need to know. He spotlights oveporexton (Orzeyful), Takeda's orexin agonist that received FDA approval in August 2026, as a potential paradigm shift in treatment. Alkermes also has a similar agent in phase 2 trials. On the diagnostic side, Guo emphasizes the importance of objective sleep testing — particularly the MSLT and CSF orexin levels — to accurately distinguish between narcolepsy type 1, type 2, and idiopathic hypersomnia before initiating treatment.
By the Numbers:
Why it matters: For the millions living with narcolepsy or idiopathic hypersomnia, oveporexton represents a potential leap from symptom management to disease-targeted therapy — and clinicians across neurology and primary care should be ready to prescribe it soon.
